Nantahala Capital Management LLC Has $2.65 Million Stock Holdings in Kodiak Sciences Inc. (NASDAQ:KOD)

Nantahala Capital Management LLC lifted its holdings in shares of Kodiak Sciences Inc. (NASDAQ:KOD - Free Report) by 287.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 266,613 shares of the company's stock after purchasing an additional 197,756 shares during the quarter. Nantahala Capital Management LLC owned 0.51% of Kodiak Sciences worth $2,653,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. Barclays PLC lifted its holdings in shares of Kodiak Sciences by 65.5% in the third quarter. Barclays PLC now owns 79,658 shares of the company's stock valued at $208,000 after purchasing an additional 31,527 shares in the last quarter. JPMorgan Chase & Co. raised its position in Kodiak Sciences by 220.9% in the 3rd quarter. JPMorgan Chase & Co. now owns 44,648 shares of the company's stock valued at $117,000 after buying an additional 30,735 shares during the last quarter. State Street Corp lifted its stake in Kodiak Sciences by 1.8% in the 3rd quarter. State Street Corp now owns 816,634 shares of the company's stock valued at $2,131,000 after acquiring an additional 14,711 shares in the last quarter. Peapod Lane Capital LLC acquired a new position in Kodiak Sciences during the 4th quarter worth approximately $1,660,000. Finally, Geode Capital Management LLC grew its stake in shares of Kodiak Sciences by 1.7% during the 3rd quarter. Geode Capital Management LLC now owns 768,740 shares of the company's stock worth $2,007,000 after acquiring an additional 12,783 shares in the last quarter. Institutional investors own 89.06% of the company's stock.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a "neutral" rating and issued a $3.00 price objective on shares of Kodiak Sciences in a research report on Monday, March 31st.

Kodiak Sciences Stock Performance

KOD traded up $0.31 on Friday, hitting $4.80. 615,630 shares of the company were exchanged, compared to its average volume of 344,196. The stock's fifty day moving average is $3.27 and its 200-day moving average is $5.46. The company has a market cap of $253.21 million, a PE ratio of -1.32 and a beta of 2.40. Kodiak Sciences Inc. has a 12 month low of $1.92 and a 12 month high of $11.60.

Kodiak Sciences (NASDAQ:KOD - Get Free Report) last released its earnings results on Thursday, March 27th. The company reported ($0.84) earnings per share for the quarter, beating the consensus estimate of ($0.90) by $0.06. As a group, equities research analysts expect that Kodiak Sciences Inc. will post -3.45 EPS for the current fiscal year.

Kodiak Sciences Company Profile

Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.